SecBot SecBot
SECBOTREPLAY Home › Report › OCGN

OCGN · Ocugen reported financial results for Q4 and full year 2025, showing…

Ocugen, Inc. · 8-K filed Mar 4, 2026 at 11:08 ET

At the news

MIXEDIMPACT 6/10

8-K filed Mar 4, 2026 at 11:08 ET

Ocugen reported financial results for Q4 and full year 2025, showing increased R&D spending and net losses, but highlighted significant clinical progress including completed enrollment in its OCU400 Phase 3 trial and positive preliminary data for OCU410. The company secured $22.5 million in financing to extend its cash runway into Q4 2026.

  • Completed enrollment in OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa; topline data expected Q1 2027
  • Positive preliminary Phase 2 data for OCU410 in geographic atrophy showed 46% lesion growth reduction
  • Secured $22.5 million in gross proceeds through a registered direct offering in January 2026
  • Cash and restricted cash totaled $18.9 million as of December 31, 2025, down from $58.8 million a year earlier

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access